Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
304 Injection vs Rituximab in B-cell NHL
NCT03980379Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 304 injection in B-cell non-Hodgkin lymphoma (2 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last measurable concentration, Area under the plasma concentration-time curve from time 0 to infinity and 6 more. Status: unknown.
02
Drugs
304 injection
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03980379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980379.